Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	5,400.00 ₩	-4.09%	488,593
11/06/26	5,630.00 ₩	-3.10%	512,955
10/06/26	5,810.00 ₩	-2.35%	556,126
09/06/26	5,950.00 ₩	+22.81%	1,050,749
08/06/26	4,845.00 ₩	-10.61%	594,556

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 12/06/2026			5-day change	1st Jan Change
5,400.00 ^KRW	-4.09%		-0.37%	-21.51%

14/04	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
03/04	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI

Market Cap	241B 159M 138M 127M 119M 222M 15.14B 226M 1.5B 584M 7.37B 598M 585M 25.51B	P/E Ratio 2024	-4.17x	P/E Ratio 2025	-33.5x
Enterprise Value	224B 147M 127M 117M 110M 206M 14.02B 209M 1.39B 540M 6.82B 554M 542M 23.63B	EV / Sales 2024	1.31x	EV / Sales 2025	8.97x
Free-Float	82.59%	Yield 2024 *	-	Yield 2025	-

14/04	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
03/04	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI
13/03	Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI
22/09/25	Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index	CI
21/08/25	An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million.	CI
11/07/25	Genome & Company announced that it has received KRW 25.7890592 billion in funding	CI
28/04/25	Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors	CI
24/04/25	Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors	CI
24/04/25	Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding	CI
24/04/25	Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion.	CI
19/07/24	Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
17/07/24	Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
24/01/24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI

1 day	-4.09%
1 week	-0.37%
Current month	-11.76%
1 month	-22.64%
3 months	-35.02%
6 months	-6.90%
Current year	-21.51%

Genome & Company Stock

Stocks

A314130

KR7314130006

Biotechnology & Medical Research

Valuation: Genome & Company

Chart: Genome & Company

Latest news : Genome & Company

Quotes and Performance

Course Extremes

Managers and Directors: Genome & Company

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	4,715	6,130
1 month	4,715	7,280
Current year	4,715	10,180
1 year	2,440	10,180
3 years	2,170	10,180
5 years	2,170	28,800
10 years	2,170	47,500

Manager	Title	Age	Since
Han-Su Park CEO	Chief Executive Officer	53	24/09/2015
Ji-Soo Bae CEO	Chief Executive Officer	55	24/09/2015

Director	Title	Age	Since
Ji-Soo Bae BRD	Director/Board Member	55	24/09/2015
Han-Su Park BRD	Director/Board Member	53	24/09/2015
Se-Hyun Jung BRD	Director/Board Member	52	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/05/25	Sang-Kyun Kim	Free	Director	40,000	0.1287%
09/05/25	Jin-kyung Seo	Free		10,000	0.0322%
09/05/25	Byung-Gyu Park	Free	Public Communications Manager	50,000	0.1608%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOME & COMPANY	-4.09%	-0.37%	+87.83%	-43.75%	164M
LONZA GROUP AG	-0.35%	+0.97%	-15.96%	-12.73%	42.96B
REVOLUTION MEDICINES, INC.	+3.11%	+3.11%	+274.29%	+507.94%	31.73B
IQVIA HOLDINGS INC.	+0.22%	-1.08%	+14.03%	-14.37%	30.22B
BEONE MEDICINES AG	+1.62%	-2.08%	-4.36%	+24.05%	28.94B
CELLTRION, INC.	+4.09%	+0.93%	+10.83%	+18.78%	23.87B
MEDPACE HOLDINGS, INC.	-1.63%	+2.88%	+53.73%	+114.36%	13.57B
ASCENDIS PHARMA A/S	+1.14%	+3.62%	-	-	13.39B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.06%	+7.59%	12.96B
IONIS PHARMACEUTICALS, INC.	-0.74%	-1.62%	+105.71%	+76.01%	12.2B
Average	+0.30%	+1.72%	+59.13%	+75.32%	21B
Weighted average by Cap.	+1.01%	+0.70%	+54.35%	+95.87%

	2024	2025
Net sales	27.74B 18.3M 15.81M 14.57M 13.64M 25.56M 1.74B 25.95M 172M 67.07M 847M 68.69M 67.23M 2.93B	24.59B 16.22M 14.01M 12.91M 12.08M 22.65M 1.54B 23M 152M 59.43M 750M 60.88M 59.58M 2.6B
Net income	-20.11B -13.27M -11.46M -10.56M -9.89M -18.53M -1.26B -18.81M -125M -48.62M -614M -49.8M -48.74M -2.13B	-6.43B -4.24M -3.66M -3.38M -3.16M -5.92M -403M -6.01M -39.85M -15.54M -196M -15.92M -15.58M -679M
Net Debt	-48.91B -32.26M -27.87M -25.68M -24.04M -45.05M -3.07B -45.75M -303M -118M -1.49B -121M -119M -5.17B	-17.86B -11.78M -10.18M -9.38M -8.78M -16.45M -1.12B -16.71M -111M -43.18M -545M -44.23M -43.29M -1.89B